TISSIUM logo

TISSIUM

Develops nerve-repair and tissue-healing polymer technologies intended to improve surgical procedures and outcomes in operating rooms.

Deep Tech
Surgical Polymers
Total Raised
$60M
Last Valuation
$400M
Headquarters
Paris, France

Overview

Tissium develops polymer-based medical technology for nerve healing, with a focus on products designed for use in surgical settings. Its current push targets adoption in the US operating room, positioning the company in advanced materials and medtech rather than AI software. The company raised $60 million in an undisclosed round dated June 24, 2026. The financing is intended to support its move into the US market, where its differentiator is a PhD-originated polymer approach to repairing nerves and improving surgical treatment options.

Funding History

1 round · Jun 2026
$60M
Total Raised
1
Valuation: $400M
Cumulative: $60M

A PhD student’s nerve-healing polymer just raised €60M to take on the US operating room

Investors not disclosed
Source

Frequently Asked Questions

How much has TISSIUM raised in total?
TISSIUM has raised a total of $60M across 1 funding round.
Who are TISSIUM's investors?
TISSIUM's investors include Undisclosed.
What does TISSIUM do?
Tissium develops polymer-based medical technology for nerve healing, with a focus on products designed for use in surgical settings. Its current push targets adoption in the US operating room, positioning the company in advanced materials and medtech rather than AI software. The company raised $60 million in an undisclosed round dated June 24, 2026. The financing is intended to support its move into the US market, where its differentiator is a PhD-originated polymer approach to repairing nerves and improving surgical treatment options.
Where is TISSIUM headquartered?
TISSIUM is headquartered in Paris, France.